AnaptysBio, Inc.
On April 20, 2026, AnaptysBio completed the spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business. Learn more First Tracks Bio here.
Anaptys now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their value to shareholders.
To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
AWARDS
NEWS
These are the top biotech companies headquartered in Biotech Beach based on 2018 revenue. Here’s the brief information including the revenue of each company.
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Immunology (ACAAI).
Shares of AnaptysBio were climbing this morning after the company released positive interim data for its experimental peanut allergy treatment. The San Diego-based company said 13 patients or 46 percent of those in its ongoing Phase IIa trial saw increased tolerance to peanuts to 500 mg.
A look at a few biotechs which should outperform the market in 2018.
A new RBC report is reasonably positive on the biotech sector for 2018 and here are some reasons why.
Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs.
Barring a huge meltdown, the S&P 500 will once again have a double-digit year of gains, and most investors should be looking at their 401(k)s and other accounts with some added holiday cheer.
JOBS
IN THE PRESS